Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

Liraglutide Helps Shed Weight in Young Children With Obesity

Todd Neale

September 13, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Michael O'Riordan

April 11, 2023

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

Adherence to US Physical Activity Guidance Flattens as Sedentary Time Creeps Up

Shelley Wood

July 26, 2019

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

L.A. McKeown

August 09, 2018

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

Liraglutide Helps Shed Weight in Young Children With Obesity

Think You Need a Statin? AHA’s Risk Calculator May Disagree

AHA Celebrates a Century by Looking Back, and Forward

Top General Cardiology and CVD Prevention News of 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Adherence to US Physical Activity Guidance Flattens as Sedentary Time Creeps Up

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content